Takara Holdings Inc. · TSE:2531
Takara — CLSA presentation (February 2013)
15 slides from Takara's conference presentation, February 2013
Slide 1: Takara Holdings Inc.
Takara Holdings Inc. February 2013 Director, Shuichiro Matsuzaki TAKARA HOLDINGS INC. Business Structure 2 Takara Holdings Inc. Inc Share owned: 100% Share owned: 70.8% Share owned: 100% Takara Shuzo Co., Ltd. Takara Bio Inc Inc. Takara Healthcare Inc. [Mothers board: 4974] 22 subsidiaries 10 subsid
Slide 2: Financial Summary / Business Performance (FY2012)
Financial Summary 3 Six Six‐Year Year Financial Summary (millions of yen) Operating income Net sales Net income 250,000 12,500 198,690 202,200 191,878 192,790 190,525 189,769 200,000 10,000 0 9,500 9,264 8,851 8,572 8,506 8,335 150,000 7,500 5,639 100,000 5,000 677 658 600 4,6 4,6 3,995 5 4,6 3,78
Slide 3: Long-Term and Medium-Term Management Plan
Long‐Term Management Plan 5 Takara Group Vision 2020 (10 years from April 2011) Grow businesses in market in Japan and overseas in which the Group can Management Goal leverage its strength, establish a balanced business structure that is readily adaptable p to changing g g conditions Toward balanc
Slide 4: Tangible Goals by Business Segment
Tangible Goals by Business Segment (millions of yen) 7 Takara Shuzo Group Takara Bio Group Takara Healthcare Net sales Net sales New Net sales plan 180,,000 000 600 03 00 178,0 0 2,600 175,50 22,70 2,567 7 23,6 20,700 19,578 2,338 18,737 166,790 2,000 11.3 12.3 13.3(e) ( ) 14.3(Plan) ( l ) 11
Slide 5: Takara Shuzo Group
Takara Shuzo Group 9 Domestic Alcoholic Beverages Business Seasonings and Raw Alcohol Business Manufacture and sale of shochu, sake, RTD, and Seasonings business for food processing and seasonings raw alcohol business (B‐to‐B) Shochu Sake Overseas Business Overseas alcoholic beverages business
Slide 6: Domestic Alcoholic Beverages Market Condition
Domestic Alcoholic Beverages Market Condition (1) 11 Trends in Japan’s Japan s Population and Alcoholic Beverages Market Scale [Units] Population: thousand people (left scale) Alcoholic beverages market: thousand kiloliters (right scale) Population (0 to 19 years old) Population (20 to 64 years ol
Slide 7: Domestic Alcoholic Beverages Business
Domestic Alcoholic Beverages Business 13 Business Strategy New product development Brand nurturing Strengthen profitability Develop highly original new Foster array of powerful Strengthen profit products with differentiated brands for premium‐range and management and promote quality mid‐range prod
Slide 8: Overseas Market Condition
Overseas Market Condition (1) 15 Trend in Scale of Global Sake Market (kiloliters ) Exports Local production 35,000 30,000 25,000 20,000 15,000 10,000 5 000 5,000 0 2005 2006 2007 2008 2009 2010 2011 <Sources> Exports: Trade Statistics of Japan, Ministry of Finance Local production: Jozo Sangyo Ne
Slide 9: Overseas Business (Takara Shuzo Group)
Overseas Business (Takara Shuzo Group) 17 Business Strategy Overseas sales (millions of yen) Expand overseas alcoholic Create a Japanese food ingredients 11,500 beverages business wholesale network 870 9,316 9,8 1 Build foundation for overwhelming Build and extend sales network 7,528 No.1 positi
Slide 10: Takara Bio Group
Takara Bio Group 19 Takara Bio Group Highlights Takara Shuzo Co., Ltd. April 2002 December 2004 (now, Takara Holdings Inc.) Takara Bio Inc. was established as a Takara Bio Inc. was listed on started the biomedical business. result of a corporate separation through the Mothers section of the incorp
Slide 11: Genetic Engineering Research Business / Gene Medicine Business
Genetic Engineering Research Business 21 Expanded lineup of research Global sales network reagents Acquired the Clontech unit of BD Biosciences in 2005 Europe China USA Highly cost competitive research Korea reagents India M Manufacturing f t i th the mostt off research reagents in Dalian, China Ope
Slide 12: iPS Cell / New Business Model for Gene Therapy
iPS Cell 23 Takara Bio Technologies in iPS Cell Research Cells Technologies related to gene therapy Gene transduction Transduction Therapeutic genes Vector development RetroNectin® method Yamanaka factors, Transduction GMP production of plasmid vectors and etc. retroviral vectors Cell
Slide 13: Takara Healthcare
25 Takara Healthcare Health Foods Business TAKARA HOLDINGS INC. Takara Healthcare 26 Business Strategy Takara Bio’s unique, cutting‐edge technologies Takara Shuzo’s marketing expertise Sell health foods through direct marketing channels Business Performance (millions of yyen) Main Products
Slide 14: Our Policy
27 Our Policy TAKARA HOLDINGS INC. Our Policy 28 Developing and nurturing products and services that are differentiated with original technologies and offer the safety and high‐quality desired by customers T k Takara Sh Shuzo G Group T k Takara Bi Bio G Group Secure stable profits in Japan Grow
Slide 15: Forward-Looking Statements
Forward‐Looking Statements Statements in this presentation, other than those based on historical fact, concerning the current plans, plans prospects, prospects strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the concl